nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

20.02.2020 | Short Communication

Intravenous arketamine for treatment-resistant depression: open-label pilot study

verfasst von: Gustavo C. Leal, Igor D. Bandeira, Fernanda S. Correia-Melo, Manuela Telles, Rodrigo P. Mello, Flavia Vieira, Cassio S. Lima, Ana Paula Jesus-Nunes, Lívia N. F. Guerreiro-Costa, Roberta F. Marback, Ana Teresa Caliman-Fontes, Breno L. S. Marques, Marília L. O. Bezerra, Alberto L. Dias-Neto, Samantha S. Silva, Aline S. Sampaio, Gerard Sanacora, Gustavo Turecki, Colleen Loo, Acioly L. T. Lacerda, Lucas C. Quarantini

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

We aimed to analyze the efficacy and safety of arketamine, the R(−)-enantiomer of ketamine, for treatment-resistant depression (TRD) in humans. Open-label pilot trial, seven subjects with TRD received a single intravenous infusion of arketamine (0.5 mg/kg); primary outcome was change in Montgomery–Åsberg Depression Rating Scale (MADRS) 24 h after. Mean MADRS dropped from 30.7 before infusion to 10.4 after one day, a mean difference of 20.3 points [CI 95% 13.6–27.0; p < 0.001]; dissociation was nearly absent. Arketamine might produce fast-onset and sustained antidepressant effects in humans with favorable safety profile, like previously reported with animals; further controlled-trials are needed.

Berman RM, Cappiello A, Anand A et al (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354. https://doi.org/10.1016/S0006-3223(99)00230-9CrossRefPubMed

Caddy C, Amit BH, McCloud TL et al (2015) Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011612.pub2CrossRefPubMed

Xu Y, Hackett M, Carter G et al (2016) Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis. Int J Neuropsychopharmacol. https://doi.org/10.1093/ijnp/pyv124CrossRefPubMedPubMedCentral

Zarate CA, Singh JB, Carlson PJ et al (2006) A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856. https://doi.org/10.1001/archpsyc.63.8.856CrossRefPubMed

Popova V, Daly EJ, Trivedi M et al (2019) Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. https://doi.org/10.1176/appi.ajp.2019.19020172CrossRefPubMed

Canuso CM, Singh JB, Fedgchin M et al (2018) Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry 175:620–630. https://doi.org/10.1176/appi.ajp.2018.17060720CrossRefPubMed

Correia-Melo FS, Argolo FC, Araújo-de-Freitas L et al (2017) Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review. Neuropsychiatr Dis Treat 13:1627–1632. https://doi.org/10.2147/NDT.S135623CrossRefPubMedPubMedCentral

Correia-Melo FS, Leal GC, Vieira F et al (2019) Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. J Affect Disord. https://doi.org/10.1016/j.jad.2019.11.086CrossRefPubMed

Fond G, Loundou A, Rabu C et al (2014) Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology 231:3663–3676. https://doi.org/10.1007/s00213-014-3664-5CrossRefPubMed

10.

Lee EE, Della Selva MP, Liu A, Himelhoch S (2015) Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis. Gen Hosp Psychiatry 37:178–184. https://doi.org/10.1016/j.genhosppsych.2015.01.003CrossRefPubMed

11.

McGirr A, Berlim MT, Bond DJ et al (2015) A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 45:693–704. https://doi.org/10.1017/S0033291714001603CrossRefPubMed

12.

Murrough JW, Iosifescu DV, Chang LC et al (2013) Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170:1134–1142. https://doi.org/10.1176/appi.ajp.2013.13030392CrossRefPubMedPubMedCentral

13.

Singh JB, Fedgchin M, Daly E et al (2016) Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry 80:424–431. https://doi.org/10.1016/j.biopsych.2015.10.018CrossRefPubMed

14.

Traynor K (2019) Esketamine nasal spray approved for treatment-resistant depression. Am J Heal Pharm 76:573–573. https://doi.org/10.1093/ajhp/zxz065CrossRef

15.

Zhang JC, Li SX, Hashimoto K (2014) R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav 116:137–141. https://doi.org/10.1016/j.pbb.2013.11.033CrossRefPubMed

16.

Yang C, Shirayama Y, Zhang J et al (2015) R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5:e632–e632. https://doi.org/10.1038/tp.2015.136CrossRefPubMedPubMedCentral

17.

Fukumoto K, Toki H, Iijima M et al (2017) Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J Pharmacol Exp Ther 361:9–16. https://doi.org/10.1124/jpet.116.239228CrossRefPubMed

18.

Zhang K, Hashimoto K (2019) An update on ketamine and its two enantiomers as rapid-acting antidepressants. Expert Rev Neurother 19:83–92. https://doi.org/10.1080/14737175.2019.1554434CrossRefPubMed

19.

Hashimoto K (2019) Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci. https://doi.org/10.1111/pcn.12902CrossRefPubMedPubMedCentral

20.

Yang C, Han M, Zhang JC et al (2016) Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine. Psychiatry Res 239:281–283. https://doi.org/10.1016/j.psychres.2016.03.034CrossRefPubMed

21.

Zanos P, Moaddel R, Morris PJ et al (2018) Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev 70:621–660. https://doi.org/10.1124/pr.117.015198CrossRefPubMedPubMedCentral

22.

White PF, Shafer A, Stanski DR, Horai Y (1985) Comparative pharmacology of the ketamine isomers: studies in volunteers. Br J Anaesth. https://doi.org/10.1093/bja/57.2.197CrossRefPubMed

23.

White PF, Ham J, Way WL, Trevor AJ (1980) Pharmacology of ketamine isomers in surgical patients. Anesthesiology 52:231–239CrossRef

24.

Vollenweider FX, Leenders KL, Oye I et al (1997) Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 7:25–38CrossRef

25.

Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389. https://doi.org/10.1192/bjp.134.4.382CrossRefPubMed

26.

Bremner JD, Krystal JH, Putnam FW et al (1998) Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS). J Trauma Stress 11:125–136. https://doi.org/10.1023/A:1024465317902CrossRefPubMed

27.

Han Y, Chen J, Zou D et al (2016) Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies. Neuropsychiatr Dis Treat 12:2859–2867. https://doi.org/10.2147/NDT.S117146CrossRefPubMedPubMedCentral

28.

Zheng W, Cai D, Xiang Y et al (2020) Adjunctive intranasal esketamine for major depressive disorder: a systematic review of randomized double-blind controlled-placebo studies. J Affect Disord 265:63–70. https://doi.org/10.1016/j.jad.2020.01.002CrossRefPubMed

29.

Daly EJ, Singh JB, Fedgchin M et al (2018) Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression. JAMA Psychiatry 75:139. https://doi.org/10.1001/jamapsychiatry.2017.3739CrossRefPubMed

30.

Fedgchin M, Trivedi M, Daly EJ et al (2019) Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol 22:616–630. https://doi.org/10.1093/ijnp/pyz039CrossRefPubMedPubMedCentral

31.

Hashimoto K, Kakiuchi T, Ohba H et al (2017) Reduction of dopamine D 2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys. Eur Arch Psychiatry Clin Neurosci 267:173–176. https://doi.org/10.1007/s00406-016-0692-7CrossRefPubMed

Titel: Intravenous arketamine for treatment-resistant depression: open-label pilot study
verfasst von: Gustavo C. Leal
Igor D. Bandeira
Fernanda S. Correia-Melo
Manuela Telles
Rodrigo P. Mello
Flavia Vieira
Cassio S. Lima
Ana Paula Jesus-Nunes
Lívia N. F. Guerreiro-Costa
Roberta F. Marback
Ana Teresa Caliman-Fontes
Breno L. S. Marques
Marília L. O. Bezerra
Alberto L. Dias-Neto
Samantha S. Silva
Aline S. Sampaio
Gerard Sanacora
Gustavo Turecki
Colleen Loo
Acioly L. T. Lacerda
Lucas C. Quarantini
Publikationsdatum: 20.02.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 3/2021
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-020-01110-5

Neu im Fachgebiet Psychiatrie

23.04.2024 | Demenz | Nachrichten

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Intravenous arketamine for treatment-resistant depression: open-label pilot study

Abstract

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Psychiatrie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Inflammatory processes linked to major depression and schizophrenic disorders and the effects of polypharmacy in psychiatry: evidence from a longitudinal study of 279 patients under therapy

Melancholic features (DSM-IV) predict but do not moderate response to antidepressants in major depression: an individual participant data meta-analysis of 1219 patients

AgNOR parameters of dorsal raphe nucleus neurons as a potential diagnostic tool which could aid the differentiation between suicidal and non-suicidal death

Fatigue and brain arousal in patients with major depressive disorder

Reduced ribosomal DNA transcription in the prefrontal cortex of suicide victims: consistence of new molecular RT-qPCR findings with previous morphometric data from AgNOR-stained pyramidal neurons

ACC Glu/GABA ratio is decreased in euthymic bipolar disorder I patients: possible in vivo neurometabolite explanation for mood stabilization

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Psychiatrie